Brazil, Cuba in bioscience R&D talks
This article was originally published in Clinica
Brazil and Cuba were this week engaged in discussions aimed at completing a series of co-operation agreements in the fields of healthcare surveillance and product development, among other things. As part of an official visit to Havana by Brazilian president Luis Inacio Lula da Silva, a team headed by health minister Jose Gomes Temporao and the director of healthcare surveillance agency Anvisa, Dirceu Raposo de Mello, discussed a range of areas of planned co-operation, from bioscientific manufacturing to product standards and QA.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.